BackgroundGraphical displays and data visualization are essential components of statistical analysis that can lead to improved understanding of clinical trial adverse event (AE) data. Correspondence analysis (CA) has been introduced decades ago as a multivariate technique that can communicate AE contingency tables using two-dimensional plots, while quantifying the loss of information as other dimension reduction techniques such as principal components and factor analysis.MethodsWe propose the application of stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for the analysis based on data derived from the Common Terminology Criteria for A...
Chis Ster A, Phillips R, Sauzet O, Cornelius V. Improving analysis practice of continuous adverse ev...
PURPOSE: To explore medications and their administration patterns in real-world patients with breast...
OBJECTIVE: To ascertain contemporary approaches to the collection, reporting and analysis of adverse...
BackgroundGraphical displays and data visualization are essential components of statistical analysis...
Abstract Background Graphical displays and data visua...
Adverse events (AEs) and concomitant medications (CMs) underreporting remains a recurrent issue in c...
Gita Thanarajasingam and colleagues' Article1 in The Lancet Oncology reports on a novel longitudinal...
International audienceDrugs are evaluated and compared during clinical trials, and the observed adve...
In clinical trials, harms (adverse events) are often reported by simply counting the number of peopl...
Objective To improve communication of harm in publications of randomised controlled trials via the d...
Objective: To improve communication of harm in RCT publications we identified researchers’ recommend...
Adverse events following the use of medical interventions are a major source of concern for patients...
BackgroundUnderreporting of harms in randomized controlled trials (RCTs) may lead to incomplete or e...
AIM: We investigate the concordance, in terms of favoring the same treatment arm, between clinician-...
ObjectiveTo improve communication of harm in publications of randomised controlled trials via the de...
Chis Ster A, Phillips R, Sauzet O, Cornelius V. Improving analysis practice of continuous adverse ev...
PURPOSE: To explore medications and their administration patterns in real-world patients with breast...
OBJECTIVE: To ascertain contemporary approaches to the collection, reporting and analysis of adverse...
BackgroundGraphical displays and data visualization are essential components of statistical analysis...
Abstract Background Graphical displays and data visua...
Adverse events (AEs) and concomitant medications (CMs) underreporting remains a recurrent issue in c...
Gita Thanarajasingam and colleagues' Article1 in The Lancet Oncology reports on a novel longitudinal...
International audienceDrugs are evaluated and compared during clinical trials, and the observed adve...
In clinical trials, harms (adverse events) are often reported by simply counting the number of peopl...
Objective To improve communication of harm in publications of randomised controlled trials via the d...
Objective: To improve communication of harm in RCT publications we identified researchers’ recommend...
Adverse events following the use of medical interventions are a major source of concern for patients...
BackgroundUnderreporting of harms in randomized controlled trials (RCTs) may lead to incomplete or e...
AIM: We investigate the concordance, in terms of favoring the same treatment arm, between clinician-...
ObjectiveTo improve communication of harm in publications of randomised controlled trials via the de...
Chis Ster A, Phillips R, Sauzet O, Cornelius V. Improving analysis practice of continuous adverse ev...
PURPOSE: To explore medications and their administration patterns in real-world patients with breast...
OBJECTIVE: To ascertain contemporary approaches to the collection, reporting and analysis of adverse...